Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
Fiche publication
Date publication
avril 2017
Journal
American journal of hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre
Tous les auteurs :
Ysebaert L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J, Sinet P, Albrecht C, Cymbalista F
Lien Pubmed
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Female, France, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Male, Middle Aged, Molecular Targeted Therapy, Protein Kinase Inhibitors, therapeutic use, Pyrazoles, therapeutic use, Pyrimidines, therapeutic use, Salvage Therapy, Treatment Outcome
Référence
Am. J. Hematol.. 2017 Apr;: